Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events.
暂无分享,去创建一个
H. Miyake | R. Ando | T. Yasui | M. Sumitomo | K. Takahara | R. Shiroki | I. Kobayashi | Toshiki Ito | K. Kanao